Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
BTK inhibitor

Velexbru (Japan) (tirabrutinib)

An investigational treatment for Primary Central Nervous System Lymphoma.

Phase 3by Ono Pharmaceutical (Deciphera Pharmaceuticals in the US)
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Drug facts

The same compound appears under different names depending on the context. Here is how to identify Tirabrutinib wherever you encounter it, plus the key facts at a glance.

Generic name
Tirabrutinib
Brand name
Velexbru (Japan)
Development codes
ONO-4059, GS-4059
International name
Velexbru
Drug class
BTK inhibitor
Manufacturer
Ono Pharmaceutical (Deciphera Pharmaceuticals in the US)
How it's taken
A 480mg dose taken by mouth once a day on an empty stomach in the PROSPECT study, continued until the disease progressed or side effects became unacceptable.

A once-daily oral BTK inhibitor for relapsed or refractory primary central nervous system lymphoma, approved in Japan since 2020 as Velexbru and under FDA review with a decision due December 18, 2026.

In the US PROSPECT study, 67% of patients responded and 44% had a complete response. It would be the first drug approved in the US specifically for this lymphoma.

Email me the day the FDA decides on Tirabrutinib

The decision is expected by December 18, 2026. One email when it is public, with what it means in plain language, plus new trials for Primary Central Nervous System Lymphoma and FDA news. Unsubscribe anytime.

You'll get, for Primary Central Nervous System Lymphoma:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Where Tirabrutinib fits

No drug is specifically approved in the United States for primary CNS lymphoma.

  • First treatment is high-dose methotrexate with rituximab and other chemotherapy, often followed by a stem cell transplant, and when the disease comes back doctors use ibrutinib, lenalidomide with rituximab, nivolumab or further chemotherapy off label.
  • Tirabrutinib would be the first BTK inhibitor with a US approval in this setting.
  • Tirabrutinib and ibrutinib have not been compared directly, and the accelerated approval would depend on the ongoing Phase 3 trial confirming benefit.

How Tirabrutinib works

Almost all primary CNS lymphomas are diffuse large B-cell lymphomas that keep themselves alive through a growth signal called the B-cell receptor pathway, often because of changes in the genes MYD88 and CD79B. That pathway runs through an enzyme called Bruton tyrosine kinase, or BTK. Tirabrutinib locks onto BTK permanently and switches the signal off, so the lymphoma cells stop dividing and die.

It is a second-generation BTK inhibitor, designed to be more selective for BTK than the first drug in the class, ibrutinib, which can mean fewer off-target effects. Because it is a small molecule taken by mouth, it crosses into the brain, which is essential for a cancer confined to the central nervous system.

Clinical trial results

In Part A of the Phase 2 PROSPECT study (NCT04947319), 48 US patients with relapsed or refractory primary CNS lymphoma took tirabrutinib alone. After a median follow-up of 11.5 months, the overall response rate was 67% and the complete response rate 44%; the median time to response was 1.0 month, the median duration of response 9.3 months, and the median progression-free survival 6.0 months, with median overall survival not reached.

Part B is testing tirabrutinib at 320mg or 480mg combined with standard methotrexate-based chemotherapy in newly diagnosed patients. IGNITE (NCT07104032), a global Phase 3 trial comparing tirabrutinib with rituximab and temozolomide in relapsed or refractory disease, is recruiting and serves as the confirmatory study.

Main registered trial: NCT04947319 on ClinicalTrials.gov. Check it for the current status, sites and contacts before asking about enrollment.

Side effects and safety

Early trial safety observations

In PROSPECT, 56.3% of the 48 patients had a grade 3 or higher treatment-emergent adverse event, and 75.0% had an adverse event of any grade that was considered related to the drug. The most frequent drug-related events were anemia (18.8%), a measles-like rash (16.7%), fatigue (14.6%), low neutrophil counts (14.6%), low lymphocyte counts (14.6%), itching (14.6%) and other rash (14.6%).

Two patients died of adverse events judged unrelated to the drug, and 1 patient stopped treatment because of an adverse event. There is no US label yet; approved BTK inhibitors as a class carry warnings about bleeding, infections, low blood counts, heart rhythm problems and second cancers.

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking Tirabrutinib

A 480mg dose taken by mouth once a day on an empty stomach in the PROSPECT study, continued until the disease progressed or side effects became unacceptable.

Development history

Tirabrutinib was discovered by Ono Pharmaceutical in Japan. Japan approved it for relapsed or refractory primary CNS lymphoma in March 2020, where it launched as Velexbru in May 2020, and added Waldenstrom macroglobulinemia and lymphoplasmacytic lymphoma in August 2020; South Korea approved it for PCNSL in November 2021 and Taiwan in February 2022.

The FDA granted Orphan Drug designation in March 2023. Ono presented the PROSPECT results in May 2025 and folded its US operations into Deciphera Pharmaceuticals, which it had acquired, in July 2025. The FDA accepted the new drug application under the accelerated approval pathway with a target action date of December 18, 2026. In June 2026 Ono filed in Japan to extend the drug to central nervous system involvement of other lymphomas.

Ask anything about Tirabrutinib
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Start withor ask

Explore Primary Central Nervous System Lymphoma trials

Common questions about Tirabrutinib

▸What is Tirabrutinib (Velexbru (Japan))?

A once-daily oral BTK inhibitor for relapsed or refractory primary central nervous system lymphoma, approved in Japan since 2020 as Velexbru and under FDA review with a decision due December 18, 2026. In the US PROSPECT study, 67% of patients responded and 44% had a complete response. It would be the first drug approved in the US specifically for this lymphoma.

▸How does Tirabrutinib work?

Almost all primary CNS lymphomas are diffuse large B-cell lymphomas that keep themselves alive through a growth signal called the B-cell receptor pathway, often because of changes in the genes MYD88 and CD79B. That pathway runs through an enzyme called Bruton tyrosine kinase, or BTK. Tirabrutinib locks onto BTK permanently and switches the signal off, so the lymphoma cells stop dividing and die. It is a second-generation BTK inhibitor, designed to be more selective for BTK than the first drug in the class, ibrutinib, which can mean fewer off-target effects. Because it is a small molecule taken by mouth, it crosses into the brain, which is essential for a cancer confined to the central nervous system.

▸What are the side effects of Tirabrutinib?

In PROSPECT, 56.3% of the 48 patients had a grade 3 or higher treatment-emergent adverse event, and 75.0% had an adverse event of any grade that was considered related to the drug. The most frequent drug-related events were anemia (18.8%), a measles-like rash (16.7%), fatigue (14.6%), low neutrophil counts (14.6%), low lymphocyte counts (14.6%), itching (14.6%) and other rash (14.6%). Two patients died of adverse events judged unrelated to the drug, and 1 patient stopped treatment because of an adverse event. There is no US label yet; approved BTK inhibitors as a class carry warnings about bleeding, infections, low blood counts, heart rhythm problems and second cancers.

▸How is Tirabrutinib taken?

A 480mg dose taken by mouth once a day on an empty stomach in the PROSPECT study, continued until the disease progressed or side effects became unacceptable.

▸Is Tirabrutinib FDA approved?

Not yet. Tirabrutinib is under FDA review for Primary Central Nervous System Lymphoma; Deciphera Pharmaceuticals has filed an application and a decision is due December 18, 2026. The FDA calendar page tracks the outcome.

▸When will the FDA decide on tirabrutinib?

The FDA's target action date is December 18, 2026. The application, for relapsed or refractory primary central nervous system lymphoma, was accepted under the accelerated approval pathway in February 2026.

▸Is tirabrutinib approved anywhere?

Yes, outside the United States. Japan approved it for relapsed or refractory PCNSL in March 2020 under the name Velexbru, and it is also approved in South Korea and Taiwan. It is not approved in the US, where an FDA decision is due December 18, 2026.

▸How is tirabrutinib different from ibrutinib for CNS lymphoma?

Both block BTK, and ibrutinib is already used off label for PCNSL. Tirabrutinib is a second-generation inhibitor designed to be more selective for BTK, which may reduce off-target effects, and it would be the first BTK inhibitor with an FDA approval for this lymphoma. They have not been compared in a trial.

▸What did the PROSPECT trial show?

In 48 US patients with relapsed or refractory PCNSL, tirabrutinib 480mg once daily produced a 67% overall response rate and a 44% complete response rate, with responses starting after a median of 1 month and lasting a median of 9.3 months. Median progression-free survival was 6.0 months. The most common drug-related side effects were anemia, rash, fatigue, low blood counts and itching.

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

  1. Deciphera Pharmaceuticals via BioSpace · 2026-02-17. Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL. https://www.biospace.com/press-releases/deciphera-pharmaceuticals-announces-u-s-food-and-drug-administration-acceptance-for-filing-of-new-drug-application-for-tirabrutinib-in-patients-with-relapsed-or-refractory-pcnsl
  2. Deciphera Pharmaceuticals · 2025-05-28. Ono Pharma Presents Positive Results from Pivotal Trial in U.S. Patients with Relapsed or Refractory PCNSL. https://www.deciphera.com/news/ono-pharma-presents-positive-results-pivotal-trial-us-patients-relapsed-or-refractory-pcnsl
  3. U.S. National Library of Medicine. Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study), NCT04947319. https://clinicaltrials.gov/study/NCT04947319
  4. Ono Pharmaceutical. News releases (NDA acceptance, February 2026; Japanese supplemental application, June 2026). https://www.ono-pharma.com/en/news/
  5. National Cancer Institute. Primary CNS Lymphoma Treatment (PDQ), Health Professional Version. https://www.cancer.gov/types/lymphoma/hp/primary-cns-lymphoma-treatment-pdq

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: November 2026.

Follow Tirabrutinib by email

We'll email you when the FDA acts on Tirabrutinib and when new trials for Primary Central Nervous System Lymphoma open. Unsubscribe anytime.

You'll get, for Primary Central Nervous System Lymphoma:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site